- --------------------------------------------------------------------------------
SEC 1344
(7-2000) Persons who potentially are to respond to the collection of
Previous versions information contained in this form are not required to
obsolete respond unless the form displays a currently valid OMB
control number.
- --------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
OMB APPROVAL
----------------------------------
OMB Number: 3235-0058
Expires: January 31, 2002
Estimated average burden
hours per response 2.50
----------------------------------
SEC FILE NUMBER 333-57468
----------------------------------
CUSIP NUMBER 58505L101
58505L119
----------------------------------
FORM 10-K
- ------
FORM 10-KSB
- ------
FORM 11-K
- ------
FORM 20-F
- ------
FORM 10-Q
- ------
FORM 10-QSB
- ------
FORM N-SAR
- ------
For the Period Ended: July 31, 2001
-------------
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION
HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.
If the notification relates to a portion of the filing checked
above, identify the Item(s) to which the notification relates:
====================================================================
Part I - Registrant Information
====================================================================
MedStrong International Corporation
-----------------------------------
Full Name of Registrant
--------------------------------------------------------------------
Former Name if Applicable
500 Silver Spur Road, Suite 303
--------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)
Rancho Palos Verdes, CA 90274
--------------------------------------------------------------------
City, State and Zip Code
PART II -- RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate)
X (a) The reasons described in reasonable detail in Part III of this
--- form could not be eliminated without unreasonable effort or expense;
X (b) The subject annual report, semi-annual report, transition report
--- on Form 10-K, Form 20-F,11-K or Form N-SAR, or portion thereof, will
be filed on or before the fifteenth calendar day following the
prescribed due date; or the subject quarterly report of transition
report on Form 10-Q, or portion thereof will be filed on or before the
fifth
(c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III -- NARRATIVE
State below in reasonble detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q,
N-SAR, or the transition report portion thereof, could not be filed within
the prescribed time period.
Due to the crisis in New York City during the week of September 10, 2001,
and the resultant interruption in communication technology, our lawyers and
accountants need additional time to complete the form 10-QSB
PART IV-- OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Jerry R. Farrar (310) 544-9900
--------------- ----- --------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports reports required under Section 13 or
15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceeding 12 months or for such shorter
period that the registrant was required to file such report(s) been filed? If
answer is no, identify report(s). X Yes No
--- ---
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected by
the earnings statements to be included in the subject report or portion
thereof? Yes No If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
MedStrong International Corporation
-----------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date September 14, 2001 By /s/ Jerry Farrar
------------------- ----------------
Jerry R. Farrar
Chief Executive Officer
and President